A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA
Maria Cristina Pirosa(Institute of Oncology Research), Luca Ceriani(St Thomas' Hospital), Alessio Bruscaggin(Institute of Oncology Research), Luca Mazzucchelli(Istituto Cantonale di Patologia), Stefan Hohaus, Jan Maciej Zaucha(Gdańsk Medical University), Lodovico Terzi di Bergamo(Institute of Oncology Research), Georg Stüssi(Institute of Oncology Research), Adalgisa Condoluci(Ente Ospedaliero Cantonale), Marcello Rodari(Humanitas University), Stefania Crisci(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Luigi Maria Larocca(Agostino Gemelli University Polyclinic), Renzo Boldorini(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Eleonora Calabretta(Dana-Farber Cancer Institute), Eugenio Borsatti(Centro di Riferimento Oncologico), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Pietro Bulian(Centro di Riferimento Oncologico), Michał Kurlapski(University Clinical Centre), Antonio Pinto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Rosaria De Filippi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Andrea Rinaldi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Salvatore Annunziata(Agostino Gemelli University Polyclinic), Martina Di Trani(Humanitas University), Alexandar Tzankov(University of Basel), Deborah Piffaretti(Institute of Oncology Research), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Carmelo Carlo‐Stella(Humanitas University), Stéphane Chauvie(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Marco Cuzzocrea(Institute of Oncology Research), Anastasios Stathis(Princess Margaret Cancer Centre), Katia Pini(Institute of Oncology Research), Matin Salehi(SIB Swiss Institute of Bioinformatics), Ilaria Zangrilli(Agostino Gemelli University Polyclinic), B. Gerber(University of Zurich), Vanessa Cristaldi(Humanitas University), Grzegorz Romanowicz(Gdańsk Medical University), Gabriela Forestieri(Institute of Oncology Research), Valter Gattei(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), C. Giordano(Federico II University Hospital), Elisabetta Merlo(Istituto Cantonale di Patologia), Gian Mauro Sacchetti(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), F Cavalli(University of Insubria), Simone Bocchetta(Institute of Oncology Research), Ilaria Romano(University of Padua), Armando Santoro(IRCCS Humanitas Research Hospital), Francesco Corrado(University of Messina), Valeria Spina(Ente Ospedaliero Cantonale), Federico Jauk(Institute of Oncology Research), G. Galimberti(Institute of Oncology Research), Fabrizio Bergesio(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo)
Cited by 19
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Advanced pancreatic carcinoma: current treatment and future challenges
|Nature Reviews Clinical Oncology|2010|791
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718